Jenburkt Pharmaceuticals Limited (BOM:524731)

Market Cap	5.08B +5.4%
Revenue (ttm)	1.79B +18.0%
Net Income	347.36M +8.3%
EPS	78.71 +8.3%
Shares Out	4.41M
PE Ratio	14.62
Forward PE	n/a
Dividend	18.00 (1.68%)
Ex-Dividend Date	Jul 11, 2025

Volume	2,492
Average Volume	1,704
Open	1,057.00
Previous Close	1,042.20
Day's Range	1,057.00 - 1,119.20
52-Week Range	944.00 - 1,410.00
Beta	0.35
RSI	71.84
Earnings Date	May 5, 2026

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. The company offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. It offers its products under the Allerzine, CartiSafe Forte, Eberjen, EC...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 779
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524731

Financial Performance

In fiscal year 2026, Jenburkt Pharmaceuticals's revenue was 1.79 billion, an increase of 18.03% compared to the previous year's 1.52 billion. Earnings were 347.36 million, an increase of 8.34%.